Marianne P. Allen

Array ( [id] => 15866271 [patent_doc_number] => 20200140539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ANEMIA [patent_app_type] => utility [patent_app_number] => 16/517965 [patent_app_country] => US [patent_app_date] => 2019-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 95865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16517965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521113 [patent_doc_number] => 12122821 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Regulation of glucose metabolism using anti-CGRP antibodies [patent_app_type] => utility [patent_app_number] => 16/510220 [patent_app_country] => US [patent_app_date] => 2019-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 58 [patent_no_of_words] => 43049 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16510220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17742620 [patent_doc_number] => 11390677 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-19 [patent_title] => Human anti-CD47 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/502751 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 17 [patent_no_of_words] => 6285 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 230 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15342669 [patent_doc_number] => 20200009226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => Compositions and Methods for Treating Stroke [patent_app_type] => utility [patent_app_number] => 16/502263 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16413293 [patent_doc_number] => 10821155 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Heparin-associated polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 16/455445 [patent_app_country] => US [patent_app_date] => 2019-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 51 [patent_no_of_words] => 74132 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16455445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052238 [patent_doc_number] => 20210261672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => ANTI-FLT-1 ANTIBODIES IN TREATING BRONCHOPULMONARY DYSPLASIA [patent_app_type] => utility [patent_app_number] => 17/255254 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17255254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18117566 [patent_doc_number] => 11548947 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/448462 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 66 [patent_no_of_words] => 45257 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16448462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293623 [patent_doc_number] => 20190389947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => Anti-Marinobufagenin Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/447181 [patent_app_country] => US [patent_app_date] => 2019-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16447181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052172 [patent_doc_number] => 20210261606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => AFFINITY CARRIER USING MUTANT VHH ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/253372 [patent_app_country] => US [patent_app_date] => 2019-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482179 [patent_doc_number] => 20220089683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => BI-AND TRI-FUNCTIONAL FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/252525 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -77 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17252525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408057 [patent_doc_number] => 20200024350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/435175 [patent_app_country] => US [patent_app_date] => 2019-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16435175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800195 [patent_doc_number] => 20200123240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => HEAVY CHAIN ONLY ANTIBODIES TO PDGF [patent_app_type] => utility [patent_app_number] => 16/425140 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16425140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649723 [patent_doc_number] => 20200087391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => ANTIBODIES TO IL-6 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/421803 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839520 [patent_doc_number] => 20210147532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHOD FOR CONTROLLING THE AFUCOSYLATION LEVEL OF A GLYCOPROTEIN COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/057223 [patent_app_country] => US [patent_app_date] => 2019-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836219 [patent_doc_number] => 20190276510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => USE OF FIBROBLAST GROWTH FACTOR 1 (FGF1)-VAGUS NERVE TARGETING CHIMERIC PROTEINS TO TREAT HYPERGLYCEMIA [patent_app_type] => utility [patent_app_number] => 16/419929 [patent_app_country] => US [patent_app_date] => 2019-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16419929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649661 [patent_doc_number] => 20200087360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => Method of treating a diarrhea disorder using a novel polypeptide [patent_app_type] => utility [patent_app_number] => 16/419860 [patent_app_country] => US [patent_app_date] => 2019-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16419860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175417 [patent_doc_number] => 20190358300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => METHOD AND COMPOSITION FOR NOVEL USE OF IGF-1 AND GARCINOL TO INDUCE CLINICAL WEIGHT LOSS [patent_app_type] => utility [patent_app_number] => 16/419983 [patent_app_country] => US [patent_app_date] => 2019-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5630 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16419983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14894009 [patent_doc_number] => 20190290770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => METHOD FOR PRESERVING AND STABILIZING PROTEINS FOR FORMULATIONS OF SANITARY, PHARMACEUTICAL AND COSMETIC PRODUCTS [patent_app_type] => utility [patent_app_number] => 16/411782 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3788 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16411782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977612 [patent_doc_number] => 20210221849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => Artificial Protein Containing Antigen-Binding Region of Antibody and Being Fused With Physiologically Active Peptide [patent_app_type] => utility [patent_app_number] => 17/052951 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052951 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770917 [patent_doc_number] => 10982006 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Heterodimeric antibodies that bind fibroblast activation protein [patent_app_type] => utility [patent_app_number] => 16/375777 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 294 [patent_figures_cnt] => 316 [patent_no_of_words] => 51288 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16375777 [rel_patent_id] =>[rel_patent_doc_number] =>)